Welcome to The Intel, the Visiopharm Newsletter that brings you our latest news and digital pathology content each month. Here are the highlights of this month:
As always, feel free to get in touch if you have any questions or would like to book a demo. You can also check out our Resources page for the latest guides, posters and webinars.
Exciting results from the clinical validation study of our PD-L1 algorithm for NSCLC!
The challenge of low inter-observer agreement among pathologists has been a critical hurdle in determining eligibility for immunotherapy treatment.
The APP, which was the first IVDR-cleared PD-L1 algorithm in the market, is here to change that narrative by providing a fully-automated, reliable detection and quantification of positive tumor cells, ensuring more consistent and accurate results.
Our clinical validation study, involving three European sites, demonstrates the substantial benefits of integrating our APP into the diagnostic workflow. The study showed that the APP assistance increased overall agreement for scoring in categories from 64% to 78% and significantly reduced misclassifications, especially around the 1% cutoff.
Visiopharm joins forces with UK NEQAS ICC & ISH to advance IHC testing and patient outcomes
Highly concerning data reveals that 25-30 % of laboratories fail to meet minimum proficiency standards when testing for critical predictive biomarkers.
In response to that, this alliance introduces a comprehensive toolkit for pathology laboratories to ensure superior patient care.
"The present figures concerning IHC testing accuracy are worrying. The direct link between test precision and patient outcomes cannot be overstated. This joint initiative, combining Visiopharm's AI-driven internal quality control with our external quality assessment, aims to significantly enhance testing quality, a critical factor in delivering optimal patient care." - Mr. Andy Dodson, Director of UK NEQAS ICC & ISH.
Groundbreaking research by the team at MD Anderson
Sammy Ferri-Borgogno, Jared K. Burks et al. have published a study showcasing an impressive pipeline that merges multi-omics platforms.
Their method reveals the complex web of interactions between different cell types and the extracellular matrix within the tumor-immune microenvironment in 3D.
Visiopharm software played a pivotal role in analyzing multiplex fluorescent images obtained via COMET. They leveraged the Phenoplex workflow for tissue segmentation, cell detection, and phenotyping, and used TissueAlign to align images of different modalities (H&E, mIF, MALDI).
Understanding the dynamics of cancer cell interactions in their native spatial context is crucial for unveiling potential targets for innovative treatments.
CND Life Sciences partners with Visiopharm on novel AI-tool to detect and quantify pathological alpha-synuclein in cutaneous nerves
CND Life Sciences is partnering with Visiopharm to introduce the groundbreaking NerValence system, a novel AI-powered tool designed to detect and quantify pathological alpha-synuclein in cutaneous nerves.
This innovation represents a significant step forward in supporting biopharmaceutical clinical trials for Parkinson’s Disease, dementia, and related disorders.
“Our work with Visiopharm has demonstrated how innovative digital technology can enhance the detection and measurement of this key biomarker to optimize drug development in neurodegenerative diseases such as Parkinson’s disease and other synuclein-based disorders.” - Todd Levine, MD, CND’s Chief Medical Officer.
